Increasing evidence suggest that pleckstrin-2 (PLEK2) acts as an oncogene in several malignancies. The present study aimed to investigate the effects of PLEK2 on osteosarcoma (OS) tumorigenesis and metastasis. PLEK2 expression in OS was analyzed via bioinformatics, reverse transcription-quantitative PCR, western blot and immunohistochemistry analyses. The Cell Counting Kit-8 (CCK-8), colony formation and EdU assays were performed to assess the role of PLEK2 in OS cell proliferation. The pro-metastatic effects of PLEK2 were assessed via the Transwell and wound healing assays. In addition, the PLEK2 downstream pathway was analyzed via bioinformatics analysis and verified via western blot analysis. The results demonstrated that PLEK2 expression was upregulated in both OS cell lines and specimens. The results of the CCK-8, colony formation and EdU assays demonstrated that PLEK2 promoted OS cell proliferation . The experiments further demonstrated that PLEK2 knockdown significantly suppressed OS growth. In addition, the Transwell and wound healing assays indicated that PLEK2 promoted OS invasiveness , which was induced by the activation of the epithelial-to-mesenchymal transition process. Bioinformatics analysis revealed that PLEK2 can activate the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) pathway, which was verified via western blot analysis. Taken together, the results of the present study suggest that PLEK2 may play a tumor-promoting role in OS via the PI3K/AKT signaling pathway.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161470 | PMC |
| http://dx.doi.org/10.3892/ol.2021.12795 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PLEK2: a potential biomarker for metastasis and prognostic evaluation in uveal melanoma.
Front Med (Lausanne)
December 2024
Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Uveal melanoma (UVM) is an aggressive tumor known for its high metastatic rate, making it necessary to delineate potential molecules that may promote the development of UVM. PLEK2 has been found to promote the progression and metastasis of some tumors, but its role in UVM has not yet been reported. Through this study, we hope to explore the effect of PLEK2 on the prognosis of UVM patients and to discover the potential functional role and intrinsic mechanism of PLEK2.
View Article and Find Full Text PDFUnveiling the role of Pleckstrin-2 in tumor progression and immune modulation: insights from a comprehensive pan-cancer analysis with focus on lung cancer.
Mol Biomed
November 2024
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Article Synopsis
- Cancer is a leading global cause of death, indicating a crucial need for new biomarkers to improve prognosis and treatment strategies, with a focus on the protein Pleckstrin-2 (PLEK2).
- This study analyzed PLEK2 expression across various cancers, finding significant overexpression in tumors which correlated with poor patient outcomes, particularly in specific cancer types.
- Functional experiments revealed that reducing PLEK2 levels slowed cancer cell growth and migration and enhanced the effectiveness of PD-1 immunotherapy, suggesting that targeting PLEK2 could improve cancer treatment.
PLEK2 promotes migration and invasion in pancreatic ductal adenocarcinoma by MMP1 through IL-17 pathway.
Mol Cell Biochem
August 2024
Division of Pancreatic Surgery, Department of General Surgery, West China Hospital of Sichuan University, Chengdu, China.
Article Synopsis
- PDAC (Pancreatic ductal adenocarcinoma) has a poor prognosis mainly due to metastasis, and the study investigates the role of PLEK2, identified as an oncogene in various tumors, on PDAC progression.
- Expression analysis showed that high levels of PLEK2 in tumor specimens correlate with poorer patient survival and advanced cancer stages, while functional assays demonstrated that PLEK2 enhances PDAC cell migration and invasion.
- The findings suggest PLEK2's potential as a therapeutic target, linking its activity to increased tumor growth and specific molecular pathways, including MMP1 regulation and activation of signaling proteins like p-ERK and p-STAT3.
PLEKv2: predicting lncRNAs and mRNAs based on intrinsic sequence features and the coding-net model.
BMC Genomics
August 2024
Shaanxi Key Laboratory for Network Computing and Security Technology, School of Computer Science and Engineering, Xi'an University of Technology, Xi'an, Shaanxi, 710048, China.
Article Synopsis
- Long non-coding RNAs (lncRNAs) are RNA molecules that don't encode proteins and are similar to mRNAs; researchers developed PLEKv2 to differentiate between lncRNAs and mRNAs effectively.
- PLEKv2 boasts a prediction accuracy of 98.7% for human datasets, outperforming several other tools by significant margins in both human and cross-species predictions.
- The PLEKv2 model not only enhances the identification of lncRNAs in primate datasets but also extends its predictive capabilities to plant RNA sequences, making it a versatile tool for biological research; it's available for free online.
Pleckstrin-2 Mediates the Activation of AKT in Prostate Cancer and Is Repressed by Androgen Receptor.
Am J Pathol
October 2024
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois. Electronic address:
Phosphoinositide 3-kinase (PI3K)-AKT and androgen receptor (AR) pathways are commonly activated in prostate cancers. Their reciprocal regulation makes advanced prostate cancers difficult to treat. The current study shows that pleckstrin-2 (PLEK2), a proto-oncoprotein involved in the activation and stabilization of AKT, connects these two pathways.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!